Sanara MedTech (SMTI) to Release Earnings on Wednesday

Key Points

• Sanara MedTech is set to release its Q2 2025 earnings on Wednesday, August 13th, with analysts predicting a loss of ($0.33) per share and revenue of $25.15 million.
• In its last quarterly earnings report, the company posted a loss of ($0.41) per share, falling short of estimates, and reported revenue of $23.43 million.
• HC Wainwright has increased its price target on the stock from $51.00 to $53.00, maintaining a "buy" rating for Sanara MedTech.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to post earnings of ($0.33) per share and revenue of $25.15 million for the quarter.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Sanara MedTech had a negative net margin of 12.48% and a negative return on equity of 29.22%. The company had revenue of $23.43 million during the quarter, compared to analysts' expectations of $23.48 million. On average, analysts expect Sanara MedTech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sanara MedTech Stock Performance

Shares of NASDAQ:SMTI traded down $0.19 during midday trading on Thursday, hitting $24.36. The stock had a trading volume of 29,834 shares, compared to its average volume of 49,154. Sanara MedTech has a 1 year low of $23.53 and a 1 year high of $39.08. The company has a quick ratio of 2.54, a current ratio of 2.77 and a debt-to-equity ratio of 1.18. The stock has a 50 day moving average price of $27.83 and a two-hundred day moving average price of $30.90.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price target on Sanara MedTech from $51.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, May 15th.

Institutional Trading of Sanara MedTech

An institutional investor recently raised its position in Sanara MedTech stock. Rhumbline Advisers boosted its position in Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) by 14.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,714 shares of the company's stock after purchasing an additional 483 shares during the quarter. Rhumbline Advisers' holdings in Sanara MedTech were worth $115,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.